ㅤTake-home message from Ahmed 2017, published in The Lancet:
This is the first study to present blinded data on the diagnostic accuracy of mpMRI and TRUS biopsy against an accurate reference standard in biopsy-naïve suspected to have prostate cancer. It represents level 1b evidence for assessment of diagnostic accuracy.
mpMRI used as a triage test may lead to approximately one quarter of men being able to omit biopsy safely, also leading to an overall 5% reduction in detection of clinically-insignificant cancers. If biopsy was directed by mpMRI findings, this may lead to a 17% increase in detection of clinically-significant cancer.
ㅤTake-home message from Lopez 2021, published in BJUI:
Local anaesthetic transperineal biopsy is putatively advantagenous for reasons of avoiding general anaesthetic and reducing complications related to the transrectal route. This international multicentre prospective cohort study demonstrates that cancer detection rates are excellent alongside good toelrabilility and good safety, especially a very low sepsis rate.
ㅤTake-home message from Rouvière 2019, published in The Lancet Oncology):
The study found that using a combination of targeted biopsies based on multiparametric MRI (mpMRI) and systematic biopsies was more effective in detecting clinically significant prostate cancer in biopsy-naive patients than systematic biopsy alone. This approach may improve the diagnostic process for patients with suspected prostate cancer.
ㅤTake-home message from Kasivisvanathan 2018, published in NEJM):
The study evaluated whether multiparametric MRI, with targeted biopsy in the presence of an abnormal lesion, was non-inferior to conventional transrectal ultrasound-guided biopsy in the detection of clinically significant prostate cancer in biopsy naive patients.
It found that the use of risk assessment with MRI before biopsy and MRI-targeted biopsy was superior to standard transrectal ultrasonagraphy-guided biopsy in men at clinical risk for prostate cancer who had not undergone biopsy previously